EIT Pharma presented new analyses from the lonafarnib development program for Chronic Hepatitis Delta (CHD) at EASL Congress ...

Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new 48-week data from the IMPACT Phase 2b ...

Alcohol policy and liver disease were central at this EASL 2026 session. Experts called for stronger labelling and prevention ...

Supplement-induced liver injury is rising as wellness supplement use grows globally. Learn more about the risks highlighted at EASL 2026.

With a historic WHO resolution adopted this week giving countries, for the first time, a mandate to address liver disease ...

Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoirData on the ...

DURHAM, N.C. and BEIJING, May 27, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient ...

Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at the EASL Congress 2026 (The ...

Reading the testimonial section of EASL’s website makes you want to scream. It’s filled with stories that shouldn’t exist: A menacing lump. A flood or fire dissolving someone’s life’s work. An ...